首页> 中国专利> 一种VEGFR2酪氨酸激酶抑制剂多肽及其应用

一种VEGFR2酪氨酸激酶抑制剂多肽及其应用

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明涉及药物领域，具体涉及用于治疗湿性型老年性黄斑变性的VEGFR2酪氨酸激酶抑制剂多肽。本发明技术方案是提供一种VEGFR2酪氨酸激酶抑制剂多肽1，其序列为SELKILIHIG，及在制备治疗湿性型老年性黄斑变性药物中的应用。本发明中的VEGFR2酪氨酸激酶抑制剂多肽1序列SELKILIHIG，可以靶向抑制VEGFR2酪氨酸激酶，抑制VEGFR2产生的生理或病理的效应，达到治疗湿性型老年性黄斑变性的效果。

著录项

公开/公告号CN103254285A

专利类型发明专利
公开/公告日2013-08-21

原文格式PDF
申请/专利权人苏州普罗达生物科技有限公司;
展开▼

申请/专利号CN201310208934.X
发明设计人罗瑞雪;
展开▼

申请日2013-05-30
分类号C07K7/06;A61K38/08;A61P27/02;
代理机构
代理人
地址 215000 江苏省苏州市高新区竹园路209号
入库时间 2024-02-19 19:15:47

法律信息

法律状态公告日

法律状态信息

法律状态
2015-03-11

发明专利申请公布后的视为撤回 IPC(主分类):C07K7/06 申请公布日:20130821 申请日:20130530

发明专利申请公布后的视为撤回
2013-09-18

实质审查的生效 IPC(主分类):C07K7/06 申请日:20130530

实质审查的生效
2013-08-21

公开

公开

相似文献

专利
中文文献
外文文献

1. 一种VEGFR2酪氨酸激酶抑制剂多肽及其应用 [P] . 中国专利： CN103254285A . 2013-08-21
2. 一种VEGFR2酪氨酸激酶抑制剂多肽及其应用 [P] . 中国专利： CN103254286A . 2013-08-21
3. SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF VEGFR2 AND VLA-4 [P] . 美国专利： US2016256523A1 . 2016-09-08

机译：合成多肽和多肽作为VEGFR2和VLA-4的抑制剂
4. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066
5. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症